Atea Pharmaceuticals | 8-K: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.53, missing the estimate of USD -0.44.

Cash, Cash Equivalents, and Marketable Securities

• As of September 30, 2025: $329.3 million.
• As of December 31, 2024: $454.7 million.

Research and Development Expenses

• Increased by $12.2 million from $26.2 million for the three months ended September 30, 2024, to $38.3 million for the three months ended September 30, 2025. This increase was primarily due to higher external spending related to the HCV Phase 3 clinical development program.

General and Administrative Expenses

• Decreased by $3.8 million from $11.0 million for the three months ended September 30, 2024, to $7.2 million for the three months ended September 30, 2025. The decrease was mainly due to lower stock-based compensation expenses.

Interest Income and Other, Net

• Decreased by $2.6 million for the three months ended September 30, 2025, compared to the same period in 2024, primarily due to lower investment balances.

Net Loss

• For the three months ended September 30, 2025: - $42.0 million.
• For the three months ended September 30, 2024: - $31.2 million.

Outlook / Guidance

• Atea Pharmaceuticals anticipates that the C-BEYOND trial will be fully enrolled by the end of 2025, with topline results expected mid-2026. The C-FORWARD trial is expected to complete enrollment by mid-2026, with results available around the end of 2026.